KRAS and Miyoshi myopathy: Notably, MM patients harboring KRAS A146 mutations had significantly higher levels of LZTR1 transcripts than patients with other oncogenic KRAS or NRAS mutations, supporting the notion that these mutants are less sensitive to LZTR1 expression.